Our Longevity Working Group has been evaluating the Rubedo Life Science company under NDA after multiple discussions over 3 months.
Scientific reviews digest: The review team included 5 PhDs (3 of which are professor / PI level) and 2 PhD-candidates. All have expressed a vote in agreement. To quantify the level of conviction, some have provided a score on a scale of 1-5 (with 5 being the most excited), the average score was 3.8
Here we are presenting an overview of the company in front of the community to decide if this gets put on-chain for an assessment from the VITA token holders via a decentralized vote.
Niklas Rindtorff, Laurence Ion, Jason Colasanti, Morten Scheibye-Knudsen, David Wilson, Tim Peterson, Ariella Coler-Reily, Avi Roy
Rubedo is building a platform for longevity medicines using “smart drugs” (prodrugs) that have the capacity to selectively be activated in target cells predicted to be pathogenic and the cause of age-related diseases
- Team formed by an exceptional mix of veteran drug hunters from Pharma and Biotech, Silicon Valley tech leaders, and world-class longevity scientists (from Stanford, etc)
- The unique discovery platform Alembic combines unparalleled computational biology and proprietary chemistry technologies
- Raised $12M Seed round led by Khosla Ventures
- All Intellectual Property (IP) is fully owned by Rubedo. Multiple patents filed. First patent has been issued and granted this year
- Rubedo developed a portfolio of lead compounds for a pipeline of multiple indications of age-related diseases
- Partnership with Cedars-Sinai Medical Center has been established to advance the first program on lung fibrosis and interstitial lung diseases
- The company attracted the interest of several major Pharma Companies for strategic partnerships
Rubedo has started developing therapeutics for idiopathic pulmonary fibrosis (IPF) and lung cancer. IPF is an orphan disease, with a potentially accelerated clearance by the FDA. They work with published and proprietary databases that they have generated in-house.
Rubedo’s proprietary ALEMBIC™ drug discovery platform is based on a synergy between sophisticated computational and chemistry strategies.
This hybrid platform enables the discovery and development of novel first-in-class engineered small molecules, such as prodrugs, designed to selectively target certain types of “bad” cells, like senescent cells, which play a key role in the progression of chronic disorders.
The first product line developed by Rubedo labs is based on engineered molecules that can selectively target a population of pro-inflammatory and pro-fibrotic cells called “Senescent Cells” (as well as other rare pathogenic cells) that arise in the body with age and diseases. Senescent cells in particular cause increased chronic inflammation, pain, and tissue decay that contribute to age-related diseases such as Pulmonary Diseases, Diabetes, Alzheimer’s, Cardio-Vascular Diseases and Cancer.
By selectively clearing the body and tissues of pathogenic cells, while preserving adjacent healthy cells, the tissues can rejuvenate again and diseases revert to improved healthy states.
Rubedo has patented technology to increase the selectivity of senolytic and rare/pathogenic-cell-targeting drugs by modifying known pharmacologically active small molecules with so-called promoeities, such as a galactose residue, to generate prodrugs that are selectively metabolized into their active form in target cells by enzymes that are specific to the target disease (e.g. SA-bGAL).
Over the past decade, a growing body of scientific evidence has demonstrated the critical role of senescent or rare (pathogenic) cells in driving aging and age-related diseases. Research has indeed shown that targeted apoptosis of senescent cells restores tissue function in response to chemotoxicity and aging in animal models (Baar et al., 2017). At Rubedo Life Sciences, they are developing a novel small molecule approach to selectively target and clear senescent or pathogenic cells from aged or pathological tissues, thereby supporting tissue regeneration and restoring organ function.
The small molecules developed from their proprietary discovery platform (ALEMBIC) are engineered to be selectively activated in target cells that emerge with age-related diseases driving the chronic degenerative pathology. Rubedo recently released in pre-print, a proof-of-concept paper where they present initial results on a tool compound that is based on a prodrug strategy. This approach takes advantage of a known enzymatic activity enriched in senescent cells, the hydrolase beta-Galactosidase, well known to be a marker of senescent cells. Their data demonstrates the strategy of converting a pan-cytotoxic drug into a selective and well tolerated senolytic prodrug capable of ameliorating age-related diseases such as frailty and the loss of cognitive and muscle function in geriatric preclinical models (Doan et al., 2020; Targeted senolytic prodrug is well tolerated and results in amelioration of frailty, muscle regeneration and cognitive functions in geriatric mice | Research Square).
Marco Quarta: Serial Entrepreneur in the Longevity therapeutics space and former Stanford University Principal Investigator in full time leadership role at Rubedo. Cofounder of Turn Biotechnologies. Marco earned a Masters degree in Biotechnology, a PhD in Neuroscience, and conducted post-doctoral training in Aging, Stem Cells Biology, and Regenerative Medicine in the leading lab of his mentor Prof. Thomas Rando at Stanford University School of Medicine. He then directed a research team at Stanford/VA Hospital Palo Alto focused on translational medical research in the fields of aging and regenerative medicine.
Marc Gallop: Chemist, drug hunter, serial entrepreneur and executive (in companies including Affimax [Nasdaq: AFFY], Xenoport [acquired] and Nurix with track records of FDA approved medicines including prodrugs) and former executive in residence at 5AM ventures. Key inventor of cell type specific promoiety chemistry.
Alex Laslavic: Computer Scientist and former Facebook lead engineer. Developer of target identification platform with a focus on differential gene expression analysis in senescent cells for neo moiety design. He is the CTO.
The team has identified a portfolio of small molecules that target signature metabolism features of rare (presumably pathogenic) cells and are currently working to test and optimize these compounds in preclinical models.
The team has filed 3 patents for its pro-moieties platform. One patent, focused on glycosidic modifications of small molecules, was granted recently.
The company is currently raising a Series A. It has plans to bring in a chief business officer to aid the team in negotiating licensing deals for assets within its IPF, oncology pipeline and in other undisclosed indication programs.
Long-form presentation: The Longevity Biotech Show: #013: Marco Quarta
- Rubedo Life Sciences Establishes Collaboration with Cedars-Sinai Medical Center to Advance Idiopathic Pulmonary Fibrosis Program
- Rubedo collaborates with Cedars-Sinai on senolytic IPF program
You can read here a couple of publications, including one early POC in pre-print (but take into account that the work described in this preprint is a simple proof of concept exercise. With the current Alembic platform, the company is pursuing and developing more sophisticated molecules or prodrugs for selective targeting of pathogenic cells): The Science | Rubedo Life Science
- Strongly Agree
- Agree(with revisions)